Truist Financial Forecasts Strong Price Appreciation for Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target boosted by equities research analysts at Truist Financial from $32.00 to $38.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s price objective indicates a potential upside of 30.81% from the company’s previous close.

AGIO has been the subject of several other research reports. Royal Bank Of Canada cut shares of Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their price target for the company from $57.00 to $28.00 in a research report on Wednesday, November 19th. Zacks Research upgraded shares of Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 4th. Leerink Partnrs upgraded Agios Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 20th. Citigroup initiated coverage on shares of Agios Pharmaceuticals in a report on Wednesday, November 26th. They set a “buy” rating and a $38.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $36.67.

Agios Pharmaceuticals Stock Up 18.1%

NASDAQ AGIO traded up $4.46 on Wednesday, reaching $29.05. The company had a trading volume of 5,795,225 shares, compared to its average volume of 900,716. The stock has a market capitalization of $1.69 billion, a PE ratio of -4.15 and a beta of 0.87. Agios Pharmaceuticals has a 12 month low of $22.24 and a 12 month high of $46.00. The firm’s 50 day moving average price is $34.53 and its 200 day moving average price is $36.36.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.15. The company had revenue of $12.88 million during the quarter, compared to analyst estimates of $10.49 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The firm’s revenue for the quarter was up 43.3% on a year-over-year basis. During the same quarter last year, the business posted $16.22 EPS. On average, research analysts expect that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 3,302 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $43.92, for a total transaction of $145,023.84. Following the transaction, the insider directly owned 61,727 shares in the company, valued at approximately $2,711,049.84. The trade was a 5.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Cecilia Jones sold 3,651 shares of the stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $36.77, for a total value of $134,247.27. Following the completion of the sale, the chief financial officer directly owned 33,870 shares of the company’s stock, valued at approximately $1,245,399.90. This represents a 9.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 7,553 shares of company stock valued at $305,001 in the last quarter. 4.93% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. First Horizon Corp acquired a new stake in Agios Pharmaceuticals during the third quarter worth $45,000. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals during the 1st quarter worth about $40,000. Quantbot Technologies LP acquired a new stake in shares of Agios Pharmaceuticals during the 3rd quarter valued at about $79,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Agios Pharmaceuticals by 16.7% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 320 shares during the period. Finally, PNC Financial Services Group Inc. raised its position in Agios Pharmaceuticals by 23.4% in the second quarter. PNC Financial Services Group Inc. now owns 4,419 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 837 shares in the last quarter.

Trending Headlines about Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: FDA expanded approval: Mitapivat (AQVESME) is now approved for anemia in adults with alpha‑ or beta‑thalassemia, covering both non‑transfusion‑dependent and transfusion‑dependent patients — a meaningful label expansion that opens a new commercial market for Agios. GlobeNewswire: U.S. FDA Approves Agios’ AQVESME
• Positive Sentiment: Market reaction: News of the approval drove premarket and intraday upside as investors priced in new revenue potential and exclusivity for this indication. Reuters: Agios Pharma shares jump on FDA expansion
• Positive Sentiment: Analyst upgrade / price target: Bank of America raised its price target to $34 and maintained a “buy” rating, providing dealer support and signaling upside vs. the current price. Benzinga: BofA raises AGIO price target
• Neutral Sentiment: Commercial timing & investor outreach: Company says AQVESME expected to be available in late January 2026 and will host an investor call/webcast; PYRUKYND® remains Agios’ U.S. brand for PK deficiency (branding split may affect marketing plans). GlobeNewswire: Commercial timing & branding
• Neutral Sentiment: Trading halt: Trading was temporarily halted for AGIO with the stated reason “News pending” ahead of the announcement — a procedural action that often precedes significant corporate disclosures and can contribute to intraday volatility.
• Negative Sentiment: REMS requirement: The FDA approval label includes a Risk Evaluation and Mitigation Strategy (REMS), which may impose prescribing and monitoring obligations that could slow uptake or limit use in some settings. Zacks: Mitapivat FDA nod with REMS

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.